Suppression of CCDC6 sensitizes tumor to oncolytic virus M1

Ying Liu,Ke Li,Wen-bo Zhu,Hao Zhang,Wen-tao Huang,Xin-cheng Liu,Yuan Lin,Jing Cai,Guang-mei Yan,Jian-guang Qiu,Liang Peng,Jian-kai Liang,Cheng Hu
DOI: https://doi.org/10.1016/j.neo.2020.12.003
IF: 6.218
2021-01-01
Neoplasia
Abstract:<p>Oncolytic virus is an effective therapeutic strategy for cancer treatment, which exploits natural or manipulated viruses to selectively target and kill cancer cells. However, the innate antiviral system of cancer cells may resistant to the treatment of oncolytic virus. M1 virus is a newly identified oncolytic virus belonging to alphavirus species, but the molecular mechanisms underlying its anticancer activity are largely unknown. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays. RNA seq analysis was used to analyze the gene alternation after M1 virus infection. Small interfering RNAs transfection for gene knockdown was used for gene functional tests. Caspase-3/7 activity was detected by Caspase-Glo Assay Systems. A mice model of orthotopic bladder tumor was established to determine the oncolytic effectiveness of the M1 virus. The expression of cleaved-Caspase 3 as well as Ki-67 in tumor cells were detected by immunohistochemical analysis. To further define the molecular factors involved in M1 virus-mediated biological function, we knocked down genes related to alphavirus' activity and found that CCDC6 plays an important role in the oncolytic activity of M1 virus. Moreover, knocked down of CCDC6 augments the reproduction of M1 virus and resulted in endoplasmic reticulum (ER) stress-induced cell apoptosis <em>in vitro</em> as well as <em>in vivo</em> orthotopic bladder cancer model. Our research provides a rational new target for developing new compounds to promote the efficacy of oncolytic virus therapy.</p>
oncology
What problem does this paper attempt to address?
The main problem this paper attempts to address is: how to enhance the oncolytic virus M1's killing effect on tumor cells by suppressing the CCDC6 gene. Specifically, researchers found that the efficacy of the oncolytic virus M1 in treating cancer is limited by the inherent antiviral systems within tumor cells. To improve the therapeutic effect of the M1 virus, the research team discovered through screening that knocking down the CCDC6 gene can significantly enhance the replication ability of the M1 virus in tumor cells and promote endoplasmic reticulum stress (ER stress)-mediated apoptosis induced by the M1 virus, thereby improving the oncolytic effect of the M1 virus. Additionally, the study explored the role of CCDC6 in regulating the type I interferon pathway, revealing the importance of CCDC6 as a potential biomarker in predicting the antitumor activity of the M1 virus. These findings provide a theoretical basis for developing new compounds to enhance oncolytic virus therapy.